Literature DB >> 20014888

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

Philipp Harter1, Felix Hilpert, Sven Mahner, Florian Heitz, Jacobus Pfisterer, Andreas du Bois.   

Abstract

Most patients with ovarian cancer relapse despite aggressive surgery and platinum-taxane-based primary chemotherapy. Further treatment depends on prior response and progression-free interval. Monotherapy is indicated in patients with so-called platinum-resistant or -refractory ovarian cancer. The standard treatment for patients with platinum-sensitive recurrent ovarian cancer is platinum-based combination chemotherapy. Cytoreductive surgery is also a treatment option in such patients. Actual treatment options and strategies in recurrent ovarian cancer will also be discussed. Furthermore, this review focuses on new drugs in the treatment of primary and recurrent ovarian cancer.

Entities:  

Mesh：

Year:  2010        PMID： 20014888     DOI： 10.1586/era.09.165

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  20 in total

1.  HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.

Authors:  Thea Eline Hetland; Arild Holth; Janne Kærn; Vivi Ann Flørenes; Claes G Tropé; Ben Davidson
Journal:  Virchows Arch       Date:  2012-04-04       Impact factor: 4.064

Review 2.  Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment.

Authors:  Bin Ai; Zhixin Bie; Shuai Zhang; Ailing Li
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

3.  CXCR7 signaling induced epithelial-mesenchymal transition by AKT and ERK pathways in epithelial ovarian carcinomas.

Authors:  Hao Yu; Linlin Zhang; Peishu Liu
Journal:  Tumour Biol       Date:  2014-10-31

Review 4.  Development of new medical treatment for epithelial ovarian cancer recurrence.

Authors:  Rosanna Mancari; Giuseppe Cutillo; Valentina Bruno; Cristina Vincenzoni; Emanuela Mancini; Ermelinda Baiocco; Simone Bruni; Giuseppe Vocaturo; Benito Chiofalo; Enrico Vizza
Journal:  Gland Surg       Date:  2020-08

5.  New developments in treatment of ovarian carcinoma: focus on trabectedin.

Authors:  Philippe A Cassier; Aude Duret; Olivier Trédan; Nicolas Carrabin; Pierre Méeus; Isabelle Treilleux; Jean-Paul Guastalla; Isabelle Ray-Coquard
Journal:  Cancer Manag Res       Date:  2010-10-01       Impact factor: 3.989

6.  The critical role of HMGA2 in regulation of EMT in epithelial ovarian carcinomas.

Authors:  Junyuan Yan; Yanling Zhang; Wenshuang Shi; Cuili Ren; Yan Liu; Yunyan Pan
Journal:  Tumour Biol       Date:  2015-08-07

7.  Surgery for relapsed ovarian cancer: when should it be offered?

Authors:  Philipp Harter; Florian Heitz; Andreas du Bois
Journal:  Curr Oncol Rep       Date:  2012-12       Impact factor: 5.075

8.  Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.

Authors:  José María del Campo; Cristiana Sessa; Carolyn N Krasner; Jan B Vermorken; Nicoletta Colombo; Stan Kaye; Martin Gore; Patrik Zintl; Javier Gómez; Trilok Parekh; Youn Choi Park; Scott McMeekin
Journal:  Med Oncol       Date:  2013-02-09       Impact factor: 3.064

9.  BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.

Authors:  T Ignatov; H Eggemann; S D Costa; A Roessner; T Kalinski; A Ignatov
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-14       Impact factor: 4.553

10.  Crk-like adapter protein is required for TGF-β-induced AKT and ERK-signaling pathway in epithelial ovarian carcinomas.

Authors:  Shaomei Cheng; Jingyan Guo; Qing Yang; Lin Han
Journal:  Tumour Biol       Date:  2014-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.